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Objective: We investigated the roles of CXC chemokine ligand 12a (CXCL12a), also known as stromal cell-
derived factor-1a (SDF-1a), in endochondral bone growth, which can give us important clues to un-
derstand the role of CXCL12a in osteoarthritis (OA).
Methods: Primary chondrocytes and tibial explants from embryonic 15.5 day-old mice were cultured
with recombinant mouse CXCL12a. To assess the role of CXCL12a in chondrogenic differentiation, we
conducted mesenchymal cell micromass culture.
Results: In tibia organ cultures, CXCL12a increased total bone length in a dose-dependent manner
through proportional effects on cartilage and bone. In accordance with increased length, CXCL12a
increased the protein level of proliferation markers, such as cyclin D1 and proliferating cell nuclear
antigen (PCNA), in primary chondrocytes as well as in tibia organ culture. In addition, CXCL12a increased
the expression of Runx2, Col10 and MMP13 in primary chondrocytes and tibia organ culture system,
implying a role of CXCL12a in chondrocyte maturation. Micromass cultures of limb-bud mesenchymal
progenitor cells (MPCs) revealed that CXCL12a has a limited effect on early chondrogenesis, but signif-
icantly promoted maturation of chondrocytes. CXCL12a induced the phosphorylation of p38 and Erk1/2
MAP kinases and IkB. The increased expression of cyclin D1 by CXCL12a was signiﬁcantly attenuated by
inhibitors of MEK1 and NF-kB. On the other hand, p38 and Erk1/2 MAP kinase and NF-kB signaling were
associated with CXCL12a-induced expression of Runx2 and MMP13, the marker of chondrocyte
maturation.
Conclusion: CXCL12a promoted the proliferation and maturation of chondrocytes, which strongly suggest
that CXCL12a may have a negative effect on articular cartilage and contribute to OA progression.
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One main cellular event of osteoarthritis (OA) is a loss of the
traits of permanent articular chondrocytes, accompanied by a
transition to the growth plate/hypertrophic chondrocyte pheno-
type1. Persistent stress on articular cartilage results in apoptosis of
these chondrocytes or formation of osteophytes through endo-
chondral ossiﬁcation2. It had been generally accepted that as much
as 90% of the articular chondrocyte is metabolically inert and
cartilage tissue has a limited regenerative capacity3. However,
recent evidences suggest that the articular cartilage is a more dy-
namic tissue, balancing death of stressed chondrocyte and renewal
through synovium-derived mesenchymal progenitor cells (MPCs)4.
In vivo evidence showed that the joint synovium has resident MPCstd. All rights reserved.
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in response to cartilage injury5. In this context, it is promising to
investigate the role of chemokines in the targeted recruitment of
MPCs to the point of cartilage injury, and subsequent chondrogenic
differentiation and maturation.
Human bone marrow-derived MPCs express a restricted set of
chemokine receptors, including cysteine (C)-X-C chemokine re-
ceptor 4 (CXCR4), CX3C chemokine receptor 1 (CX3CR1), CXCR6,
CCR1 and CCR76. Among them, CXCR4 is a key component in the
migration of MPCs7e9. The CXC chemokine ligand 12a (CXCL12a),
also designated as stromal cell-derived factor-1 alpha (SDF-1a), is
the major ligand of CXCR4 and is elevated in both synovial ﬂuid and
tissue of OA10,11. While the CC chemokines, such as CCL2 (MCP-1),
CCL3 (MIP-1a), CCL4 (MIP-1b), and CCL5 (RANTES), are expressed
by chondrocytes, the source of CXCL12a in the joint is mainly sy-
novial ﬁbroblast but not cartilage per se12. On the contrary, their
receptor CXCR4 is expressed in chondrocytes, but not in synovio-
cytes10,12. Furthermore, we have identiﬁed upregulation of CXCR4
RNA and protein expression in cartilage in a rat model of post-
traumatic OA13. The expression level of CXCL12a in lining and
sublining layers of OA synovial tissue is comparable to that of
rheumatoid arthritis, and OA joint ﬂuid also shows higher levels of
CXCL12a12,14. Indeed, synovectomy of the knee joint signiﬁcantly
decreased the serum level of CXCL12a in OA patients10. Hypoxic
condition strongly induced the production of CXCL12a in OA syn-
oviocytes, but cytokines such as transforming growth factor (TGF)-
b, interleukin (IL)-1b, and tumor necrosis factor-a (TNFa) failed to
augment CXCL12a expression in conjunction with hypoxia14.
Increased CXCL12a in OA tissue can promote the recruitment of
CXCR4-positive MSCs into injured cartilage. Several lines of evi-
dence revealed that CXCL12a/CXCR4 axis-mediated recruitment of
MSCs is pivotal in damaged tissue repair in other disease con-
ditions7,15e18. A recent in vivo study showed that the intra-articular
injection of meniscus stem/progenitor cells promotes cartilage
regeneration and ameliorates OA through CXCL12a/CXCR4 axis-
mediated progenitor cell homing19. It is not clear, however,
whether this protective effect of CXCL12a/CXCR4 axis directly de-
pends on just the recruitment of MPCs or an additional paracrine
effect of CXCL12a on chondrogenic differentiation of MPCs as well.
Actually, the expression of CXCL12a and CXCR4 is down-regulated
during chondrogenesis of human MPCs, but the role of CXCL12a/
CXCR4 axis in chondrogenic differentiations has not been
elucidated20.
On the contrary to reparative effect through MPCs, CXCL12a/
CXCR4 signaling can also contribute to the disruption of cartilage
homeostasis by the induction of Runx2 and pushing chondrocyte
towards terminal maturation and apoptosis21,22. In addition,
CXCL12a is known to increase the expression of matrix metal-
loprotease (MMP)-3 and -13 in chondrocytes, resulting in me-
chanical disruption of chondrocyteematrix associations12,23,24. In
fact, the disruption of CXCL12a/CXCR4 signaling with AMD3100
signiﬁcantly reduced cartilage matrix degradation and attenuated
the severity of OA in a guinea pig OA model25. Although the
CXCL12a/CXCR4 axis is a good candidate chemokine for recruit-
ment of MPCs, these catabolic effects on articular cartilage can
present a major barrier in its clinical application26,27.
Although cumulative efforts have been made to delineate the
role of CXCL12a in chondrocyte physiology, little is known about
the role during chondrogenic differentiation and chondrocyte
proliferation. Furthermore, the subcellular signaling pathways
downstream of the CXCL12a/CXCR4 axis that regulate proliferation
and maturation of chondrocytes have not been fully elucidated. We
provide herein clear evidence on the crucial roles of CXCL12a in
both proliferation and maturation of chondrocytes. At the subcel-
lular level, CXCL12a/CXCR4 axis directly activated NF-kB as well asactivated p38 and Erk1/2 MAP kinase pathways, which were
responsible for the induction of cyclin D1, Runx2, and MMP13.
Materials and methods
Reagents and antibodies
Recombinant mouse CXCL12a was from PeproTech (Rochy Hill,
NJ). Rabbit polyclonal antibodies for Sox9, Col2, Col10, PCNA, Runx2
and MMP13 and mouse monoclonal antibody for cyclin D1 were
purchased from Abcam (Cambridge, UK). Rabbit antibodies against
p-IkB, IkB, p-Erk1/2 (pY202/204), p-p38 (T180/Y182), and p38 MAP
kinasewere obtained from Cell Signaling Technology (Beverly, MA).
Rabbit polyclonal antibody for Erk1/2 from BD Biosciences (San
Jose, CA) and mouse monoclonal antibody for b-actin from Sig-
maeAldrich (St. Louis, MO) were used for Western blot analysis.
Tibia organ culture
Tibiae isolated from E15.5 were equilibrated in a-MEM-based
organ culture media at 37C for 24 h and cultured as described30,31.
Tibia length was measured at the beginning and end of culture
using an eyepiece. Then, recombinant mouse CXCL12a or control
was added for 6 days, with media change every other day. For
morphometric analysis, intact tibia explants were stained in Alcian
Blue and Alizarin Red-S solution, and photographed under a stereo
microscope (Nikon). For histological analyses, tibiae were ﬁxed in
4% buffered paraformaldehyde overnight, embedded in parafﬁn,
cut in 5-mm-thick sections and stained with Safranin-O. Immuno-
histochemical analyses for PCNA, Runx2, Col10, and MMP13 were
performed. PCNA or Runx2 positive cells within a 200  200 mm2
window were counted under a microscope and the area staining
positive for Col10 and MMP13 was quantiﬁed with Bioquant Osteo
software (Nashville, TN). Sections from at least ﬁve tibiae per
concentrationwere analyzed, using at least three sections per tibia.
For all antibodies, negative controls were used following the same
protocol in the absence of the primary antibody.
Isolation and culture of mouse primary chondrocytes
Primary chondrocytes were isolated from the humerus, radius
and ulna of 15.5-day-old mouse embryo (E15.5) as previously
described28. Isolated bones were equilibrated in a-minimum
essential medium (a-MEM)-based organ culture media supple-
mented with 0.2% BSA, 0.25 mM ascorbic acid, 1 mM beta-
glycerophosphate, 0.25% L-glutamine and 0.25% penicillin/strepto-
mycin at 37C with 5% CO2 overnight. They were incubated in
trypsin-EDTA with gentle rocking for 15 min at 37C and then
digested with 3 mg/ml of Collagenase P (SigmaeAldrich) in com-
plete Dulbecco's modiﬁed essential media (DMEM) for 2 h. The
fractioned cells were ﬁltered through a 40-mm nylon mesh (BD
Bioscience), and collected by centrifugation. Cell culture was per-
formed in 2:3 DMEM:F12 medium with 10% fetal bovine serum
(FBS), and 0.25% L-glutamine. For starvation and chemokine treat-
ment, DMEM with 1% FBS was used. Primary chondrocytes at
passage 0 were used for experiments because of their dedifferen-
tiation capacity during passage29.
Quantitative RT-polymerase chain reaction (PCR) analysis
Total RNAwas isolated from primary chondrocyte cultures using
a Qiagen RNeasy Mini kit according to the manufacturer's protocols
(Qiagen, Mississauga, Ontario, Canada). cDNA was synthesized us-
ing ELIPS Biotech Reverse Transcription prime kit (Daejeon, Korea)
with random hexamer primer. Quantitative real-time RT-PCR
G.-W. Kim et al. / Osteoarthritis and Cartilage 23 (2015) 966e974968analysis was performed using the Applied Biosystems VIA III Real-
Time PCR system with QuantiTest SYBR Green PCR Kit (QIAGEN).
The gene expression levels were normalized to those of Glyceral-
dehyde 3-phosphate dehydrogenase (Gapdh). The sequence of
primers used for quantitative RT-PCR are as follows: mSox9
(NM_011448) (F, CAGCCCCTTCAACCTTCCTC, R, TGATGGTCAGCG-
TAGTCGTATT), mAgc1 (NM_007424) (F, CCTGCTACTTCATCGACCCC,
R, AGATGCTGTTGACTCGAACCT), mCol2a1 (NM_031163) (F, GGG
AATGTCCTCTGCGATGAC, R, CAGGCGCACCATCTCTGAT), mRunx2
(NM_001146038) (F, ATGCTTCATTCGCCTCACAAA, R, GCACTCACT-
GACTCGGTTGG), mCol10a1 (NM_009925) (F,TTCTGCTGCTAATGTT
CTTGACC, R, GGGATGAAGTATTGTGTCTTGGG), mMMP13 (NM_0086
07) (F,CTTCTTCTTGTTGAGCTGGACTC, R, CTGTGGAGGTCACTGTA-
GACT), mCXCL12a (NM_001012477) (F,TGCATCAGTGACGGTAAA
CCA, R, TTCTTCAGCCGTGCAACAATC), mCXCR4 (NM_009911)
(F,GAGGCCAAG GAAACTGCTG, R, GCGGTCACAGATGTACCTGTC).
Protein isolation and Western blotting
Protein from primary chondrocyte cultures (n ¼ 4 independent
isolations) was extracted by 300 mL RIPA buffer supplemented with
proteaseandphosphatase inhibitor (RocheDiagnostics, Indianapolis,
IN), and then microfuged for 20 min at 10,000 g. Total cell lysate
(20e30 mg of protein) was separated by 10% SDS-polyacrylamide gel
electrophoresis and transferred to a polyvinylidene diﬂuoride
membrane (Immobilon-P; Millipore Corporation, Billerica, MA). The
transferred membrane was blocked using 5% skim milk at room
temperature (RT) for at least 1 h, and then membrane-bound pro-
teins were probed with primary antibodies against Sox9, Col2,
aggrecan, cyclin D1, PCNA, Runx2, MMP13, p-IkB, p-Erk1/2 and
p-p38. The membrane was washed in TBST and incubated with
horseradish peroxidase (HRP)econjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at RT for 1 h, followed by
detection using enhanced chemiluminescent detection reagents
(GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Immunostaining for BrdU (5-Bromo-20-deoxyuridine) incorporation
by chondrocytes
The effect of CXCL12a on chondrocyte proliferationwas assessed
with an in vitro BrdU cell proliferation assay. Brieﬂy, primary
chondrocytes (2  104/well) from E15.5 were cultured in serum-
free DMEM on gelatin-coated coverslips for 24 h, and then stimu-
lated with vehicle or CXCL12a. After incubation for 18 h, the media
were supplemented with 10 mM of BrdU solution (Invitrogen,
Camarillo, CA), and cells were incubated at 37C for an additional
6 h. Then cells were ﬁxed with 70 % ethanol, and BrdU antibody
(1:1000 dilution) was added overnight at 4C. BrdU incorporation
in primary chondrocytes was visualized with a Streptavidinebiotin
conjugated secondary antibody, and quantiﬁed. Negative controls
underwent the same procedure, but without the primary antibody.
Embryonic limb mesenchyme micromass culture
Micromass cultures were performed as described previ-
ously32,33. Brieﬂy, limb buds from E11.5 mice were dissected and
mesenchymal cells were isolated by digestion in Dispase II (Roche,
Indianapolis, IN) with gentle shaking for 90 min. Cells were
resuspended in 3:2 F12:DMEM media with 10% FBS, 0.25%
Penicillin-Streptomycin and 0.25% L-glutamine, and plated at a
density of 2.5  105 cells/10-ml drop. Four hours later, micromass
culture media supplemented with 1 mM b-glycerophosphate and
0.25 mM ascorbic acid with or without CXCL12a was added, and
cells were differentiated with media change every other day. For
chondrogenic differentiation, Alcian Blue stainingwas conducted atday 3, 5, and 7, and extracted with 6 M guanidine hydrochloride,
and the absorbance of supernatant was measured at 600 nm. For
chondrocyte maturation, cells were stained with alkaline phos-
phatase (ALP) stain at day 7, 9, and 13. Positive area for ALP was
quantiﬁed with Bioquant Osteo software. RNAwas extracted at day
1, 3, 5, 7, 9, and 13 and followed by real-time RT-PCR for CXCL12a,
CXCR4, Sox9, Col2a1, Agc, Runx2, Col10a1, and MMP13. Total cell
lysate was harvested at day 3 and subjected to Western blot ana-
lyses for early markers, e.g., Sox9, Col2, Agc, and cyclin D1. Lysate
extracted at day 7 was analyzed for late marker, Runx2, Col10, and
MMP13.
Statistical analysis
All data were shown as the means ± 95% conﬁdence intervals.
The ManneWhitney U test was used to compare differences be-
tween two groups and the KruskaleWallis test for multiple groups.
The presence of a linear trend in the length of tibia organ culture by
CXCL12a was tested with trend analysis in one-way analysis of
variance (ANOVA) test. P < 0.05 was considered statistically sig-
niﬁcant. All analyses were conducted using SPSS version 14.0
software (SPSS, Chicago, IL).
Results
CXCL12a increases total bone length in ex vivo culture
To investigate the role of CXCL12a in endochondral bone
growth, we conducted ex vivo tibia organ culture. Tibiae obtained
from E15.5 mice were cultured in the presence or absence of
CXCL12a for 6 days. CXCL12a increased the total bone length in
dose-dependent manner (P for trend¼ 0.004), and the highest dose
of CXCL12a (250 ng/ml) had statistical signiﬁcance compared to
controls (P ¼ 0.038) [Fig. 1(A), (B)]. However, the proportion of
Alizarine Red and Alcian Blue positive area was not affected by
CXCL12a, implying that CXCL12a promotes the growth of both
cartilage and the transition to calciﬁed bone [Fig. 1(C)]. Next, we
assessed the histological appearance of tibia growth plates with
Safranin-O staining. The relative proportion of the proliferative
zone (PZ) and hypertrophic zone (HZ) (relative to the entire growth
plate) was not inﬂuenced by CXCL12a. Although it had no statistical
signiﬁcance, the prehypertrophic zone (PHZ) showed a decreasing
trend in the CXCL12a-treated group, implying an early transition to
hypertrophic chondrocyte [Fig. 1(D)e(F)]. These results suggest
that CXCL12a promotes endochondral bone formation by affecting
both proliferation and maturation of chondrocyte, as well as
turnover to bone.
CXCL12a promotes chondrocyte proliferation
We next investigated the effects of CXCL12a on chondrocyte
proliferation. Primary chondrocytes were cultured for 24 h in the
presence of CXCL12a, and RNA and protein expressionwas analyzed
by real-time PCR and Western blot. At RNA and protein level, Sox9
expression was not affected by CXCL12a. The expression of aggre-
canwas slightly increased by 100 ng/ml of CXCL12a at the RNA level
(P ¼ 0.029), and by 250 ng/ml of CXCL12a at the protein level.
However, expression of Collagen 2 was not affected at RNA and
protein level [Fig. 2(A), (B)]. We then examined the regulation of
chondrocyte proliferation by CXCL12a. CXCL12a increased the
protein expression of proliferation markers, such as cyclin D1 and
proliferating cell nuclear antigen (PCNA) [Fig. 2(B)]. To validate the
effect of CXCL12a on chondrocyte proliferation, we performed im-
munostaining to detect BrdU incorporation into primary chon-
drocytes in monolayer culture. As expected, CXCL12a signiﬁcantly
Fig. 1. CXCL12a increases bone growth in tibia organ culture. (A) E15.5 tibiae were cultured with or without recombinant mouse CXCL12a for 6 days and then stained with Alcian
Blue for cartilage and with Alizarin Red for bone. (B) The length of tibiaeat beginning and end of culture was measured, and the difference is shown as growth over 6 days. The linear
trend of increased length by CXCL12a was tested with one-way ANOVA. Data were presented as means ± 95% CI of nine experiments. *P < 0.05 compared to control group in
ManneWhitney U test. (C) The proportion of calciﬁed bone stained with alizarin red was measured. (D) Histological analysis of tibia organ cultures. Sections of cultured tibiae were
stained with Safranin-O to visualize the structure of the growth plate. (E) Enlarged microscopic images for clarifying the morphology of chondrocytes. PZ, PHZ and HZ were deﬁned
based on the morphological characteristics of cells. (F) The proportion of hypertrophic and PZs relative to the total growth plate was measured. Data were presented as means ± 95%
CI of eleven experiments.
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[Fig. 2(C)]. We then conﬁrmed the expression of PCNA in tibia organ
culture. In resting and proliferating layer of tibia growth plate,
CXCL12a signiﬁcantly increased the number of PCNA-positive
chondrocytes [Fig. 2(D)]. These results indicate that CXCL12a pro-
motes the proliferation of chondrocytes, which may contribute to
the lengthening of bone.
CXCL12a promotes chondrocyte maturation
We then studied the effects of CXCL12a on the expression of
chondrocyte maturation markers in monolayer culture. As shown
in Fig. 3, 250 ng/ml of CXCL12a signiﬁcantly increased the expres-
sion of Runx2 in RNA (P ¼ 0.048) and protein levels [Fig. 3(A), (B)].
The RNA expression of Col10 was increased by 100 ng/ml of
CXCL12a (P < 0.001), and that of MMP13 also showed a similar
pattern, but did not reach statistical signiﬁcance (P ¼ 0.083)
[Fig. 3(A)]. However, the protein expression of Col10 and MMP13
was signiﬁcantly increased by 250 ng/ml of CXCL12a [Fig. 3(B)].
Immunohistochemical analyses of tibia organ cultures demon-
strated that CXCL12a increased the expression of Runx2, Col10, and
MMP13 in the hypertrophic layer of the growth plate, which isconsistent with the expression pattern in monolayer culture
[Fig. 3(C)e(E)].
CXCL12a promotes the maturation of chondrocyte in limb-bud
mesenchymal cell micromass cultures
To determine whether CXCL12a affects early chondrogenesis
from MPCs, we performed in vitro high-density (2.5  105 cells/
10-ml drop) micromass culture using limb-bud MPCs. Micromass
cultures were treated with or without CXCL12a and Alcian blue
incorporation into the extracellular matrix of micromass cultures
was measured at day 3, 5, and 7. In accordance with the mono-
layer culture of primary chondrocyte, CXCL12a did not affect
Alcian blue incorporation in micromass culture, implying that
CXCL12a has a limited role in early chondrogenic differentiation
of MPCs [Fig. 4(A)]. To clarify the role of CXCL12a in chondrocyte
maturation, ALP staining was conducted onmicromass cultures at
day 7, 9, and 13. 250 mg/ml of CXCL12a signiﬁcantly increased ALP
activity after 9 days in culture [Fig. 4(B)]. Real-time RT-PCR ana-
lyses revealed that exogenous CXCL12a did not affect the
expression of endogenous CXCL12a and its receptor, CXCR4 dur-
ing micromass culture. The RNA expression of Sox9 and Col2a1
Fig. 2. CXCL12a increases proliferation of chondrocytes. (A) RNA expression of chondrogenic marker genes such as Sox9, Agc, and Col2a1 were analyzed by real-time RT-PCR.
Primary chondrocytes obtained from E15.5 mice were treated with CXCL12a or control for 24 h, and total RNA was prepared for real-time RT-PCR. *P < 0.05 compared to CXCL12a
non-treated group. (B) E15.5 primary chondrocytes were cultured in the presence of CXCL12a for 24 h, and subjected to Western blot analysis to evaluate protein level of chon-
drogenic markers such as Sox9, Col2, and aggrecan, and proliferating markers, cyclinD1 and PCNA. (C) In vitro BrdU cell proliferation assay in monolayer-cultured chondrocytes.
Primary chondrocytes from E15.5 were cultured with or without 250 ng/ml of CXCL12a for 18 h, then supplemented with 0.03 mg/ml of BrdU solution and incubated at 37C for 6 h.
The relative percentage of BrdU-positive cells was assessed in 20-microscopic ﬁelds. (D) Expression of PCNA in tibia organ culture. E15.5 tibiae were cultured with or without
250 ng/ml of CXCL12a for 6 days, and immunohistochemistry analysis for PCNA was conducted. The positive cells in ﬁve areas of 200  200 mm2 of the PZ were counted, and data
were presented as mean ± 95% CI. *P < 0.05.
Fig. 3. CXCL12a increases the maturation of chondrocytes. (A) E15.5 primary chondrocytes were treated with CXCL12a for 24 h. Then real-time RT-PCR was performed to evaluate
the expression of hypertrophic marker genes, such as Runx2, Col10a1, and Mmp13. (B) Effects of CXCL12a (250 ng/ml) on Runx2, Col10, and MMP13 protein level were examined by
Western blotting in primary chondrocytes. (C, D, E) E15.5 tibiae cultured with or without 250 ng/ml of CXCL12a for 6 days were harvested and processed for immunohistochemical
detection of hypertrophic marker proteins Runx2, Col10 and MMP13. Similar results were seen in ﬁve separate experiments, and representative ﬁgures were presented. Runx2
positive cells were counted in ﬁve areas of 200  200 mm2 of the HZ in each sample. Positive area of Col10 and MMP13 staining in the HZ was quantiﬁed in ﬁve samples per group.
*P < 0.05 compared to control group in ManneWhitney U test.
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but the protein expression of Sox9, Collagen 2, and aggrecan
showed no difference when assessed at day 3 [Fig. 4(C), (D)].
Markers for chondrocyte maturation, Runx2, Col10, and MMP13
were increased by 250 ng/ml of CXCL12a at the protein level after7 days of culture [Fig. 4(E)]. Although the RNA expression of
Col10a1 and Mmp13 showed a trend towards increase at day 7 in
CXCL12a-treated cultures, this was not statistically signiﬁcant,
and Mmp13 transcript levels actually decreased at day 13
[Fig. 4(C)].
Fig. 4. CXCL12a promotes the maturation of chondrocyte in limb-bud mesenchymal cell micromass culture. (A) Mouse limb bud-derived MPCs were plated in a density of
2.5  105 cells/10-ml drop, cultured in the absence (media control) or presence of CXCL12a, and then stained with Alcian blue at day 3, 5, and 7. Alcian blue stain was chemically
extracted and the absorbance of supernatant was quantiﬁed at 600 nm wavelength. (B) Micromass cultures were stained with ALP to visualize chondrocyte maturation after 7, 9,
and 13 days in culture. ALP staining was quantiﬁed by histomorphometric analysis with Bioquant Osteo software. Data represent the mean ± 95% CI. Scale bars in (A) and (B)
represents 1 mm. (C) Quantitative analyses for target genes during micromass culture by real-time RT-PCR. MPCs seeded in a high-density were cultured in the absence or presence
CXCL12a (250 ng/ml), and serially harvested at the indicated time for real-time RT-PCR analyses. Data are the mean ± 95% CI of samples in triplicate which is representative of three
independent experiments. *P < 0.05 compared to control group using ManneWhitney U non-parametric test. (D) Micromass cultures were harvested following 3 days of incubation
in chondrogenic media supplemented with 100 or 250 ng/ml of CXCL12a and examined byWestern blot for chondrogenic and proliferation markers. (E) Total lysate frommicromass
culture incubated for 7 days was subjected to Western blot analyses for Runx2, Col10, and MMP13.
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dependent on p38 and Erk1/2 MAP kinases and the NF-kB pathway
To elucidate the signals downstream of CXCL12a, we examined
the activation of NF-kB andMAP kinase pathways by CXCL12a. After
overnight starvation, primary chondrocytes were treated with
250 ng/ml of CXCL12a, which strongly induced the phosphorylation
of p38 and Erk1/2 MAP kinases as well as that of IkB [Fig. 5(A)].
However, Jnk MAP kinase, Akt and Smad1/5 phosphorylation were
not activated by CXCL12a (data not shown). We then explored
whether these activated signaling cascades contribute to the in-
duction of cyclin D1, Runx2, and MMP13 expression, using phar-
macological inhibitors. Primary chondrocytes were cultured with
the p38 MAP kinase inhibitor (SB203580, 10 mM), the MEK1/Erk
inhibitor (PD98059, 10 mM) or the inhibitor of NF-kB nuclear
translocation (JSH-23, 10 mM) in the presence or absence of
CXCL12a for 24 h. Treatment with PD98059, or JSH-23 signiﬁcantly
attenuated the induction of cyclin D1 by CXCL12a, but SB203580
failed to show a prominent suppression of cyclin D1, suggesting the
involvement of Erk1/2 and NF-kB signaling in CXCL12a-mediated
cyclin D1 induction. For maturation markers, CXCL12a-mediated
Runx2 expression was attenuated by all of the three inhibitors,
SB203580, PD98059, and JSH-23. On the other hand, the induction
of MMP13 by CXCL12a was inhibited by SB203580 and JSH-23, but
only partially suppressed by MEK1/Erk inhibitor, PD98059, sug-
gesting the presence of additional upstream factor [Fig. 5(B)].Discussion
In this study, we provide in vitro evidence that CXCL12a pro-
motes the proliferation and maturation of chondrocytes in tibia
organ culture and primary culture. Additional in vitro data using
MPCs micromass culture also indicated that CXCL12a increased
chondrocyte maturation, but not early chondrogenic differentia-
tion. The effects of hypertrophic markers appeared to be stronger at
the protein level than at the transcript level, suggesting the
involvement of posttranscriptional effects. At the subcellular level,
CXCL12a activated p38 and Erk1/2 MAP kinases and the NF-kB
signaling pathway, which mediate the CXCL12a-mediated induc-
tion of cyclin D1, Runx2 and MMP13 [Fig. 5(C)]. These data on
developmental role of the CXCL12a/CXCR4 axis in chondrocyte
maturation might also be relevant to processes involved in the
repair of cartilage damage, for example in OA.
There have been many attempts to recruit endogenous mesen-
chymal cells to differentiate into cartilage to repair damaged
articular cartilage or meniscus34,35. A recent study revealed that the
CXCL12a/CXCR4 axis enhances the engraftment of intra-articularly
delivered-meniscus stem/progenitor cells and promotes meniscus
regeneration19. It is noteworthy that CXCL12a did not affect early
chondrogenic differentiation and expression of its receptor CXCR4
decreased during early chondrogenesis in our micromass culture
condition (Fig. 4). Considering these results, despite its role in
recruitment of MPCs, the CXCL12a/CXCR4 axis appears to have little
Fig. 5. CXCL12a activates p38 and Erk1/2 MAP kinases and NF-kB signaling. (A) CXCL12a-induced activation of signaling pathways. Starved E15.5 primary chondrocytes were
stimulated by 250 ng/ml of CXCL12a for indicated times and then subjected to Western blot analysis of several phosphorylated signaling proteins. (B) Effects of each signaling
pathways on the expression of CyclinD1, Runx2, and MMP13. Starved primary chondrocytes were treated with 250 ng/ml of CXCL12a in the presence of p38 MAP kinase-2 inhibitor
(SB203580, 10 mM), MEK1 inhibitor (PD98059, 10 mM), or inhibitor of NF-kB nuclear translocation (JSH-23, 10 mM) for 24 h. (C) Model of CXCL12a-induced chondrocyte activation.
CXCL12a produced in synovial ﬁbroblast binds to CXCR4 expressed by chondrocytes, and subsequently activates Erk1/2 and p38 MAP kinases and NF-kB signaling, which are partly
responsible for the increased expression of cyclin D1, Runx2, and MMP13.
G.-W. Kim et al. / Osteoarthritis and Cartilage 23 (2015) 966e974972effect on early chondrogenic differentiation. Furthermore, CXCL12a
promoted the maturation of chondrocytes to a hypertrophic
phenotype, including MMP13 expression and endochondral ossi-
ﬁcation. These results suggest that the CXCL12a/CXCR4 axis may be
a less effective chemokine system in a MPCs-based cartilage
regeneration approach. A recent study also showed that CXCL12a
promotes BMP2-induced osteogenic differentiation of MPCs, indi-
cating distinct roles of CXCL12a in different MPCs-derived line-
ages36. Further studies will be needed to ﬁnd a more suitable
system that not only promotes in MPCs recruitment, but also pre-
vents subsequent differentiation of chondrocytes to hypertrophy
and osteogenesis.
In addition to CXCL12a, other CXC chemokines, such as CXCL8
(interleukin-8) and CXCL1 (growth-related oncogene a) are also
knowntopromotehypertrophicdifferentiationof chondrocyte37e40.
In articular chondrocyte cultures, CXCL8 and CXCL1 lead to chon-
drocyte hypertrophy and calciﬁcation through the activation of the
p38 MAP kinase pathway and p38-dependent activation of trans-
glutaminase 2 (TG2)37. The common signaling property of these CXC
chemokines, including CXCL12a, is the activation of p38MAP kinase.
The p38 MAP kinase pathway is known to be involved in the IL-1-
induced activation of chondrocytes, including MMP13, COX-2 and
nitric oxide synthase induction,which are allmajor biologic changes
in OA41. We also showed that CXCL12a activation of p38MAP kinase
was partly responsible for MMP13 expression. However, the genetic
orpharmacologic inhibitionof p38MAPkinasepathway in invivoOA
models led to severe cartilage degenerative changes, suggesting thatp38 MAP kinase pathway has a role in maintaining cartilage in vivo,
in contrary to in vitro IL-1-treated conditions42,43. These discrep-
ancies between in vitro and in vivodatamay result from thepresence
of a direct activator of p38 MAP kinase, such as IL-1 and CXCL12a in
in vitro conditions, but not in vivo. Another, maybe more likely,
possibility is that thedurationorefﬁcacyofp38MAPkinasepathway
blockade can account for the differential responses.
In this study, we provided the ﬁrst evidence that the CXCL12a/
CXCR4 axis activates NF-kB signaling in chondrocyte, which is
critical to CXCL12a-induced cyclin D1 and MMP13 production.
Several reports have indicated that NF-kB signaling exerts a regu-
latory role in endochondral bone formation44e46. In the develop-
ment of the chick limb bud, overexpression of IkB to block NF-kB
activity results in arrested limb outgrowth44. In metatarsal organ
culture and primary chondrocyte culture in vitro, the loss of func-
tion of p65, a major component of the canonical NF-kB pathway,
attenuated longitudinal bone growth due to decreased chondrocyte
proliferation and differentiation, whereas gain of functionwith p65
overexpression led to the opposite result45. In addition, the inhi-
bition of IKKa resulted in the arrest of chondrocyte maturation at
the pre-hypertrophic stage in micromass culture of articular
chondrocytes46. All these ﬁndings indicate that NF-kB contributes
to chondrocyte proliferation and hypertrophic differentiation, and
our data suggest that the CXCL12a/CXCR4 axis can be another major
upstream regulator of NF-kB signaling in chondrocyte.
Our in vitro results demonstrated that CXCL12a activates p38
and Erk1/2 MAP kinases and the NF-kB signaling pathway, and
G.-W. Kim et al. / Osteoarthritis and Cartilage 23 (2015) 966e974 973these signaling pathways have different effects on proliferation and
maturation of chondrocytes. Among them, p38MAP kinase and NF-
kB were essential for CXCL12a-mediated MMP13 induction, while
the MEK/Erk pathway has only partially involved. On the contrary,
MEK/Erk and NF-kBwere critical in cyclin D1 induction by CXCL12a,
but p38 MAP kinase pathway had a limited effect. Similar phe-
nomenon has already been reported in IL-1-mediated MMP13 in-
duction in articular chondrocyte, where MMP13 expression was
blocked by the p38 inhibitor SB203580, but not by the MEK in-
hibitor PD9805947. In addition, we had shown that MEK inhibition
reduced chondrocyte proliferation induced by TGF-alpha48. How-
ever, Chiu et al. reported that CXCL12a did not activate p38 MAP
kinase, and activated only ERK1/2 signaling that was responsible
for the induction of MMP13 via activator protein 1 (AP-1) in human
articular chondrocyte23. In that study, the primary human articular
chondrocytes were used between the second and sixth passages,
which can cause the dedifferentiation of chondrocyte that result in
the different signaling properties23. In addition, we can ﬁnd that
only media change can induce a transient Erk1/2 signaling activa-
tion that terminated within 15 min, while other signals were not
activated by media change [Fig. 5(A)]. Our data suggest that
although both p38 and Erk1/2 MAP kinases are potent inducers of
AP-1 activity by increasing the expression of c-fos and c-jun49,50,
they may have a different role in CXCL12a-induced proliferation
and maturation of chondrocyte.
In summary, our ﬁndings indicate that CXCL12a functions to
promote chondrocyte proliferation and maturation, and reveal that
CXCL12a/CXCR4 axis activates p38 and Erk1/2 MAP kinase as well
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